HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Kalyn Dabbs

Kalyn Dabbs

Director of Communications

Kalyn Dabbs serves as Genprex’s Director of Communications. Kalyn is responsible for developing and implementing internal and external communication and marketing plans, managing the company’s website and social media strategy, drafting and updating communication materials and providing organizational leadership on communication and marketing initiatives. Kalyn has more than a decade of experience leading external communication programs in both B2B and B2C marketing settings. Prior to joining Genprex, Kalyn has worked for public companies within the health industry, specifically with medical devices and consumer packaged goods, leading global communication and marketing campaigns for commercial FDA-approved products. She has also worked for public relations agencies, serving both public and private clients across a variety of industries while garnering experience in internal and external communications, investor relations, media relations, social media, content development and crisis communications.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference Sep 8
  • Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy Aug 18
  • Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies Aug 3
  • Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer Jun 22
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use